Melanoma Trial, Not Yet Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People of any age (including newborns) with a personal or family history of an unusual type, pattern, or number of cancers or tumors
• People with a personal or family history of conditions that may increase cancer risk, such as certain inherited syndromes, birth defects, chromosomal differences, or unusual exposures (like certain medications or radiation)
• People diagnosed with, or related to someone diagnosed with, Li-Fraumeni syndrome or a related condition (a hereditary condition linked to multiple types of cancer)
• People diagnosed with, or related to someone with, a RASopathy — a group of conditions including Noonan syndrome, Costello syndrome, Cardiofaciocutaneous syndrome, Legius syndrome, and related conditions
• People with a tumor type linked to a gene called DICER1 (such as certain lung, kidney, ovarian, or thyroid tumors), or a known or suspected change in the DICER1 gene
• People affected by, or related to someone affected by, an inherited bone marrow failure syndrome (such as Fanconi anemia, Diamond Blackfan anemia, Dyskeratosis congenita, Shwachman Diamond syndrome, or similar conditions)
• People with a personal or family history of unusual melanoma (skin cancer), including at a very young age or in large numbers
• People with Fanconi anemia aged 12 or older (or aged 8–11 with certain worrying symptoms such as mouth sores or difficulty swallowing)
• People diagnosed with chordoma or a related tumor at any age
• People with a personal or family history of certain familial cancers or benign tumors, including bladder, brain, lung, certain skin cancers, or nerve-related tumors
• People with a known inherited gene change (mutation) in TP53, or a close relative of someone who carries this mutation
• People with a known or suspected inherited gene change in a RASopathy-related gene (such as BRAF, HRAS, KRAS, NRAS, PTPN11, or others)
• People with a known gene change linked to inherited bone marrow failure syndromes (such as changes in FANC genes, RPS19, DKC1, MPL, or ELA2)

Who may not be able to join:

• There are no specific rules that would prevent someone from completing the eligibility screening survey for this trial — anyone who believes they may meet the above criteria can take part in the initial screening

Important: Always verify eligibility with the trial site directly before applying.